The activities developed by the Biodonostia HRI are in line with the PCTI 2030 (Science, Technology and Innovation Plan) and with the RIS3 Smart Specialisation Strategy (Personalised Health); they are listed in its Strategic R&D&I Plan 2021-2025 and in the specific Strategic Lines defined in said Plan.

The Biodonostia HRI, in the framework of the Strategic R&D&I Plan 2021-2025 and as an agent of the RVCTI (Basque Science, Technology and Innovation Network), therefore works to develop its Strategic Lines of Translational Research, Innovation and Technological Medicine, Internationalisation and Management and Infrastructures. These lines mobilise all of the Institute’s own resources and those of the Donostialdea IHO, mainly in order to proceed with research, development and innovation activities, with the collaboration of other RVCTI agents and companies.


The Ageing Strategy, named with the acronym IKAGURE-BD, is carried out by means of collaboration between different Research Groups form IIS Biodonostia and OSI Donostialdea, also involving several players in the field who work in healthcare. +info


Personalised Precision Medicine
The Cross-Cutting Area of Personalised Precision Medicine, PPM, mainly consists of three IIS Biodonostia Research Groups: Hepatic Diseases (Dr Bañales), Gastrointestinal Genetics (Dr Garcia Etxebarria) and Molecular Oncology (Dr Lawrie). +info


Mainly through the Innovation Support Unit (ISU), the Strategy promotes people being entrepreneurs and innovating, taking advantage of the innovative potential of other people and organisations in the area, managing innovative ideas and projects to make them a reality. +info